Top

Annals of Hematology

Published in:

01-08-2014 | Letter to the Editor

Successful discontinuation of eculizumab therapy in a patient with aHUS

Authors: Jeffrey J. Pu, Abigail Sido

Published in: Annals of Hematology | Issue 8/2014

Excerpt

Dear Editor, …

Campistol JM, Arias M, Ariceta G et al (2013) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment: a consensus document. Nefrologia 33(1):27–45. doi:10.3265/Nefrologia.pre2012.Nov.11781 PubMed

Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. NEJM 368:2169–2181. doi:10.1056/NEJMoa1208981 PubMedCrossRef

Laurence J (2012) Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol 10:1–12PubMed

Frimat M, Tabarin F, Dimitrov JD et al (2013) Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122(2):282–292. doi:10.1182/blood-2013-03-489245 PubMedCrossRef

Ohanian M, Cable C, Halka K (2011) Reduced dose maintenance eculizumab in atypical uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol 3:45–50. doi:10.2147/CPAA.S23687 PubMedCentralPubMed

Parker C (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373:759–767. doi:10.1016/S0140-6736(09)60001-5 PubMedCrossRef

Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic uremic syndrome: case report. Transplant Proc 42:4353–4355. doi:10.1016/ j.transproceed. 2010.09. 125 PubMedCrossRef

Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T (2010) Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 55:708–711. doi:10.1053/j.ajkd.2009.08.01 PubMedCrossRef

Prescott HC, Wu HM, Cataland SR, Baiocchi RA (2010) Eculizumab therapy in an adult with plasma-exchange refractory atypical hemolytic uremic syndrome. Am J Hematol 85:976–977. doi:10.1002/ajh.21862 PubMedCrossRef

10.

Hillmen P, Muus P, Röth A et al (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162(1):62–73. doi:10.1111/bjh.12347 PubMedCentralPubMedCrossRef

Title: Successful discontinuation of eculizumab therapy in a patient with aHUS
Authors: Jeffrey J. Pu
Abigail Sido
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 8/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-013-1972-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2014

Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial

Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study

Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era

Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis

Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials